130 results
Page 2 of 7
8-K
EX-10.3
sizo7
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
8-K
EX-99.1
0m4 t517jsm05nkn2
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
8nzrvdurl0umon v4
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
EX-99.1
3hk69 fnd
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
j1wia5ft
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.2
6c6dex z7zxv3
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
EX-99.1
asduow4lju0zk
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
ula0l0fc7hs nq9
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
pzyf4j n5jp
16 May 22
Additional proxy soliciting materials
6:32pm
DFAN14A
ctd86p7p6rl2 b23b
16 May 22
Additional proxy materials by non-management
2:04pm
DFAN14A
EX-99.1
o1cd78dtko
16 May 22
Additional proxy materials by non-management
2:04pm
8-K
EX-99.1
6y3vdc 55
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm
DFAN14A
b6uquu
12 May 22
Additional proxy materials by non-management
2:06pm
DFAN14A
EX-99.1
9i4vgqjh18goy7
12 May 22
Additional proxy materials by non-management
2:06pm
DEFA14A
9wwz1h0bn1 6z5
11 May 22
Additional proxy soliciting materials
4:49pm